FDA Response Bolsters Affiris’ Plans for Potential Parkinson’s Vaccine Affitope

FDA Response Bolsters Affiris’ Plans for Potential Parkinson’s Vaccine Affitope
The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company and provided guidance related to designing the upcoming trial. Based on that response, Affiris intends ... read more
Source: Parkinson’s News TodayPublished on 2020-01-29By Marisa Wexler